Norovirus vaccine (mRNA-1403)
Phase 3 interim analysis did not meet early-success criteria; the trial continues with an extra cohort.
What it is
mRNA-1403 is Moderna's vaccine candidate against norovirus, the common cause of stomach bugs and outbreaks. The Phase 3 study is still blinded. At its interim analysis, the data did not meet the criteria for early success, so Moderna plans to enroll an additional cohort.
Why it matters to the stock. A norovirus vaccine would open a new indication for the company, but the interim result pushes back any filing and makes the program a longer-dated bet.
News
Moderna Q2 2026 revenue rises to $145 million; 2026 guidance kept, R&D outlook cut
Moderna reported Q2 2026 total revenue of $145 million, up from $142 million a year earlier, while net product sales fell to $94 million from $114 million.
Earnings